Effect of allogeneic blood transfusion on levels of IL‑6 and sIL‑R2 in peripheral blood of children with acute lymphocytic leukemia

Zhao,Hui; Zhou,Huayou; Cao,Qiong; Wang,Chunyan; Bai,Jing; Lv,Piao; Zhao,Fang

doi:10.3892/ol.2018.8760

Effect of allogeneic blood transfusion on levels of IL‑6 and sIL‑R2 in peripheral blood of children with acute lymphocytic leukemia

Authors:
- Hui Zhao
- Huayou Zhou
- Qiong Cao
- Chunyan Wang
- Jing Bai
- Piao Lv
- Fang Zhao
View Affiliations

Affiliations: Department of Blood Transfusion, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Clinical Laboratory, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Pediatrics, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Stomatology, Nanfang Hospital, Southern Medical University/The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: May 21, 2018 https://doi.org/10.3892/ol.2018.8760
Pages: 849-852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effect of allogeneic blood transfusion on the expression of interleukin‑6 (IL‑6) and soluble interleukin‑2 receptor (sIL‑2R) in peripheral blood of children with acute lymphoblastic leukemia (ALL) was investigated. A total of 91 ALL children admitted to Nanfang Hospital from June 2014 to January 2017 were selected as the study group. Patients were randomly divided into allogeneic blood transfusion group (n=38) and non‑transfusion group (n=53). In addition, a total of 64 healthy children were also selected from June 2014 to January 2017 as the control group. Patients in allogeneic blood transfusion group were transfused with red blood cell suspension and machine‑collected platelets, while patients in non‑transfusion group were not treated with blood transfusion. Peripheral venous blood was collected before and at 4, 8 and 12 weeks after blood transfusion to prepare serum. Serum IL‑6 and sIL‑2R levels were measured by enzyme‑linked immunosorbent assay (ELISA). Before transfusion, serum levels of IL‑6 and sIL‑2R were significantly lower in the study group than those in control group (p<0.05), and no significant differences in serum levels of IL‑6 and sIL‑2R were found between the allogeneic blood transfusion and non‑transfusion group. After transfusion, serum levels of IL‑6 and sIL‑2R were stable for 12 weeks in the non‑transfusion group, while IL‑6 and sIL‑2R levels were significantly increased in the allogeneic blood transfusion group. The results showed that serum level of IL‑6 and sIL‑2R was increased in ALL patients with allogeneic blood transfusion, which resulted in reduced antibody production and decreased cellular immunity. The patients had low immunity, and attention should be paid on the pathogen infection prevention.

View Figures

View References

1	Sanders JE, Im HJ, Hoffmeister PA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, Bryant EM and Appelbaum FR: Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood. 105:3749–3756. 2005. View Article : Google Scholar : PubMed/NCBI
2	Pieters R and Carroll WL: Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am. 55:1–20, ix. 2008. View Article : Google Scholar : PubMed/NCBI
3	Izbicki G, Rudensky B, Na'amad M, Hershko C, Huerta M and Hersch M: Transfusion-related leukocytosis in critically ill patients. Crit Care Med. 32:439–442. 2004. View Article : Google Scholar : PubMed/NCBI
4	Deng CH and Zhang QP: Leukemia stem cells in drug resistance and metastasis. Chin Med J (Eng1). 123:954–960. 2010.
5	Bhojwani D and Pui CH: Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol. 14:e205–e217. 2013. View Article : Google Scholar : PubMed/NCBI
6	Pui C-H, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 359:1909–1915. 2002. View Article : Google Scholar : PubMed/NCBI
7	Tzounakas VL, Seghatchian J, Grouzi E, Kokoris S and Antonelou MH: Red blood cell transfusion in surgical cancer patients: Targets, risks, mechanistic understanding and further therapeutic opportunities. Transfus Apheresis Sci. 56:291–304. 2017. View Article : Google Scholar
8	Cata JP, Wang H, Gottumukkala V, Reuben J and Sessler DI: Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 110:690–701. 2013. View Article : Google Scholar : PubMed/NCBI
9	Koehl U, Sörensen J, Esser R, Zimmermann S, Grüttner HP, Tonn T, Seidl C, Seifried E, Klingebiel T and Schwabe D: IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol Dis. 33:261–266. 2004. View Article : Google Scholar : PubMed/NCBI
10	Tvedt TH, Lie SA, Reikvam H, Rye KP, Lindås R, Gedde-Dahl T, Ahmed AB and Bruserud Ø: Pretransplant levels of CRP and interleukin-6 family cytokines; effects on outcome after allogeneic stem cell transplantation. Int J Mol Sci. 17:E18232016. View Article : Google Scholar : PubMed/NCBI
11	Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B and Vo A: Interleukin-6, a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation. 101:32–44. 2017. View Article : Google Scholar : PubMed/NCBI
12	Murakami S: Soluble interleukin-2 receptor in cancer. Front Biosci. 9:3085–3090. 2004. View Article : Google Scholar : PubMed/NCBI
13	Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, et al: Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 30:1635–1640. 2012. View Article : Google Scholar : PubMed/NCBI
14	Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, et al: Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: In combination with the International Prognostic Index. J Cancer Res Clin Oncol. 131:73–79. 2005. View Article : Google Scholar : PubMed/NCBI
15	Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, Yasuda I, Shimizu M, Murakami N, Yoshikawa T, et al: Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 91:705–714. 2012. View Article : Google Scholar : PubMed/NCBI
16	Bhojwani D, Yang JJ and Pui CH: Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am. 62:47–60. 2015. View Article : Google Scholar : PubMed/NCBI
17	Pape A, Stein P, Horn O and Habler O: Clinical evidence of blood transfusion effectiveness. Blood Transfus. 7:250–258. 2009.PubMed/NCBI
18	Smolen JS and Maini RN: Interleukin-6: A new therapeutic target. Arthritis Res Ther. 8(Suppl 2): S52006. View Article : Google Scholar : PubMed/NCBI
19	Soker M, Colpan L, Ece A, Devecioğlu C and Haspolat K: Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia. Med Oncol. 18:51–57. 2001. View Article : Google Scholar : PubMed/NCBI
20	Stachura A, Król R, Poplawski T, Michalik D, Pomianowski S, Jacobsson M, Aberg M and Bengtsson A: Transfusion of intra-operative autologous whole blood: Influence on complement activation and interleukin formation. Vox Sang. 100:239–246. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T, Fujiwara M, Nishisaka T, Sasaki N, Sadahira Y, et al: Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One. 8:e787302013. View Article : Google Scholar : PubMed/NCBI